Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

Peripheral T-cell (PTCL) and NK cell lymphomas have poor survival with conventional cytotoxic chemotherapy. Because angiogenesis plays an important role in the biology of PTCL, a fully humanized anti-VEGF antibody, bevacizumab (A), was studied in combination with standard CHOP chemotherapy (ACHOP) t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3872505/
https://ncbi.nlm.nih.gov/pubmed/23786456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.816700
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi